Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist

CMS set the 2027 physician reimbursement rate for Sanuwave’s CPT code 97610 at $314.54, approximately 21% below the 2026 rate of $397.81. The 2027 hospital outpatient rate is $235.04, approximately 15% above its 2026 rate of $204.98. Sanuwave said it is evaluating options for a continued response.

Analysis

The key issue is not the headline rate cut in isolation, but whether SNWV’s eligible treatments are concentrated in physician offices or can migrate to hospital outpatient departments. The 2027 schedule makes the office setting less favorable while improving the hospital outpatient rate; that may alter site-of-care economics and provider willingness to use the code. A shift is not automatic: clinical workflow, facility billing rules, patient access, and the economics of the full episode of care may constrain it. The hospital-rate increase is therefore a possible offset, not evidence of revenue replacement.

Near term, expect pressure on sentiment and potentially a reassessment of SNWV’s reimbursement exposure. The actual earnings impact cannot be established from the release: investors need code-level claims by place of service, payer mix, and the share of company revenue tied to 97610. The company’s statement that it is evaluating options is not evidence that an appeal, coding change, or alternative payment path will succeed.

Over 1–3 months, watch for management to quantify exposure and describe provider response; over 6–18 months, the structural risk is lower utilization or substitution toward other wound-care approaches if office economics weaken. Conversely, hospital adoption could cushion the impact. The contrarian point: a single code’s rate change may be over-weighted if it represents a small portion of SNWV economics, but the offset may be overestimated if providers cannot readily shift settings.

Key Decisions for Investors

• No high-conviction directional trade on this release alone. Avoid adding to SNWV until management provides 97610 revenue or claims exposure by place of service and payer; the downside is real but its scale is unverified.
• Set a 1–3 month diligence alert for SNWV guidance, claims-volume commentary, and any CMS or coding developments. Reassess if office-based utilization falls or the company indicates hospital outpatient growth is not offsetting the impact.
• For existing SNWV exposure, size risk against the possibility that the office reimbursement reduction affects more volume than hospital outpatient rates can recover. Do not assume the two setting changes net out.
• Thesis is weakened if SNWV demonstrates that 97610 is immaterial to revenue, or reports stable eligible utilization and a meaningful shift to hospital outpatient care. It is strengthened by reduced code volume, lower reimbursement in other relevant settings, or a negative guidance revision.